DFD-O6, topical high potency steroid, is used in treatment of plaque psoriasis
Dr Reddys Laboratories announced that the Company through its subsidiary, Promius Pharma LLC, has out-licensed the future development, manufacturing and commercialisation rights of DFD-06, a topical high potency steroid, to Encore Dermatology Inc. The drug is intended to be used for treatment of moderate to severe plaque psoriasis.Under the terms of the agreement, Encore will be responsible for the commercialisation of DFD-06 in the United States. Promius Pharma is eligible to receive certain pre and post commercialisation milestone payments of up to USD 32.5 million, followed by fixed royalty payments on net sales.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
